Study guide

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias

Key Takeaways Explain This Topic AI

In atrial fibrillation with pre-excitation (Wolff-Parkinson-White), AV nodal blocking drugs such as adenosine, verapamil and digoxin are contraindicated because they accelerate accessory pathway conduction.

CHA2DS2-VASc scores of 2 or more in men and 3 or more in women indicate anticoagulation with a direct oral anticoagulant in non-valvular atrial fibrillation.

Fusion beats, capture beats and AV dissociation confirm ventricular tachycardia; a broad complex tachycardia after myocardial infarction should be treated as VT.

Last updated: September 2026

Arrhythmias and conduction abnormalities represent core high-yield clinical territories in MRCP(UK) Part 1. Candidates must master acute emergency stabilization algorithms, hemodynamic stratification, electrocardiographic criteria, pharmacotherapy via the Vaughan-Williams classification, and stroke risk stratification in atrial fibrillation.

1. Atrial Fibrillation & Atrial Flutter

Atrial fibrillation (AF) is characterized by chaotic, uncoordinated atrial activation resulting in irregular ventricular response and loss of effective atrial systole. Atrial flutter arises from a macro-re-entrant circuit, most commonly around the tricuspid valve annulus within the right atrium (cavotricuspid isthmus), producing regular "sawtooth" flutter waves (typically negative in leads II, III, and aVF at an atrial rate of ~300 bpm with 2:1 AV block yielding a ventricular rate of ~150 bpm).

Acute Management & Hemodynamic Status

Hemodynamically Unstable (Adverse Features): Shock (systolic BP <90 mmHg), syncope, ongoing myocardial ischaemia, or acute pulmonary oedema. Mandates immediate synchronized DC cardioversion (starting at 120–150 J biphasic, escalating as required) under sedation or general anaesthesia. Intravenous unfractionated heparin should be initiated promptly.

Hemodynamically Stable: The therapeutic pathway branches into rate control versus rhythm control, coupled with systematic thromboembolic risk assessment.

Rate Control vs Rhythm Control Strategies

According to NICE and ESC guidelines, rate control is the preferred default initial strategy for most patients unless specific rhythm control indications are met:

Rate Control First-Line: Suitable for patients >65 years, those with underlying coronary artery disease, patients who are sedentary, or those without significant heart failure symptoms. Monotherapy options include:

Standard Beta-Blockers: Bisoprolol (1.25–10 mg once daily) or metoprolol tartrate/succinate.

Rate-Limiting Calcium Channel Blockers: Diltiazem (60–120 mg TDS) or verapamil (40–120 mg TDS). Crucial contraindication: Never administer diltiazem or verapamil in patients with heart failure with reduced ejection fraction (HFrEF) or co-prescribed with beta-blockers due to risk of complete heart block and severe myocardial depression.

Digoxin: Indicated as monotherapy only in sedentary elderly patients or as an add-on agent in patients with concurrent heart failure. Digoxin acts by augmenting vagal tone to the AV node; it is ineffective during physical exertion or acute stress where sympathetic tone overrides vagal influence. Target serum concentration is 0.5–0.9 ng/mL.

Target Heart Rate: Initial resting heart rate <110 bpm (lenient rate control per RACE II trial); if symptoms persist, titrate toward strict rate control (<80 bpm at rest and <110 bpm during moderate exercise).

Rhythm Control Indications: Preferred when there is a reversible precipitating trigger (e.g., chest infection, hyperthyroidism, acute alcohol excess), new-onset AF (<48 hours), heart failure clearly precipitated by AF, younger patients (<65 years), or patients who remain symptomatic despite optimal rate control.

Pharmacological Cardioversion: IV flecainide (Class Ic) is highly effective for rapid restoration of sinus rhythm. Strict absolute contraindication: Flecainide must never be given in structural heart disease, left ventricular systolic dysfunction, or coronary artery disease (ischaemic heart disease) due to high risk of fatal proarrhythmia demonstrated in the CAST trial. In structural heart disease or HFrEF, IV amiodarone (300 mg over 20–60 minutes, followed by 900 mg over 24 hours) is the antiarrhythmic of choice.

Thromboembolic Risk Assessment & Anticoagulation

Thromboembolic prophylaxis is guided by the validated CHA2DS2-VASc score:

  • Acronym Clinical Risk Factor Points
  • C Congestive heart failure (or LV ejection fraction <=40%) 1
  • H Hypertension (or on antihypertensive therapy) 1
  • A2 Age >=75 years 2
  • D Diabetes mellitus 1
  • S2 Stroke, TIA, or thromboembolism history 2
  • V Vascular disease (prior MI, peripheral arterial disease, complex aortic plaque) 1
  • A Age 65–74 years 1
  • Sc Sex category: Female 1

Treatment Thresholds:

Score 0 in males or 1 in females: No anticoagulation indicated.

Score 1 in males: Anticoagulation should be strongly considered.

Score >=2 in males or >=3 in females: Oral anticoagulation is mandatory.

Direct Oral Anticoagulants (DOACs): First-line therapy over warfarin for non-valvular AF. Includes direct Factor Xa inhibitors ( apixaban , rivaroxaban , edoxaban ) and the direct thrombin inhibitor ( dabigatran ). DOACs offer superior or equivalent stroke prevention with significantly lower rates of intracranial haemorrhage and do not require routine INR monitoring.

Valvular AF Exception: Patients with moderate-to-severe rheumatic mitral stenosis or mechanical prosthetic heart valves are categorized as "valvular AF". DOACs are contraindicated in these populations; warfarin (target INR 2.5–3.5 depending on valve prosthesis type and position) remains strictly required.

Bleeding Risk Assessment: Assessed using the ORBIT score (preferred by NICE) or HAS-BLED score. A high bleeding score is not an automatic contraindication to anticoagulation; rather, it highlights modifiable risk factors (e.g., uncontrolled hypertension, concurrent NSAID/antiplatelet use, excess alcohol consumption) requiring clinical remediation.

Anticoagulation Timing Around Cardioversion

AF Duration <48 Hours: Cardioversion can be performed immediately. Give therapeutic low-molecular-weight heparin (LMWH) or a DOAC at presentation. Post-cardioversion, patients with CHA2DS2-VASc >=1 (males) or >=2 (females) require long-term anticoagulation; those with score 0 (males) or 1 (females) require 4 weeks of anticoagulation.

AF Duration >=48 Hours (or Unknown Duration): High risk of pre-existing left atrial appendage (LAA) thrombus. Requires either:

Minimum of 3 weeks of continuous, therapeutic oral anticoagulation prior to elective cardioversion, followed by at least 4 weeks of therapeutic oral anticoagulation post-procedure (regardless of whether sinus rhythm is maintained).

Transoesophageal Echocardiography (TOE) Guided Strategy: If early cardioversion is desired, a TOE is performed to definitively exclude LAA thrombus. If clear, cardioversion proceeds immediately under full anticoagulation coverage, followed by >=4 weeks of oral anticoagulation.

2. Narrow Complex Tachycardias & Pre-Excitation

A narrow complex tachycardia exhibits a QRS duration <120 ms, indicating that ventricular depolarisation proceeds normally through the specialized His-Purkinje system. These originate at or above the AV junction.

Atrioventricular Nodal Re-entrant Tachycardia (AVNRT)

AVNRT is the most common regular supraventricular tachycardia (~60% of cases), typically presenting in young women with sudden-onset palpitations, neck fluttering (due to right atrial contraction against a closed tricuspid valve creating cannon 'a' waves), and polyuria (atrial stretch triggering atrial natriuretic peptide release).

Mechanism: Dual pathways within the AV node: a slow pathway (short refractory period) and a fast pathway (long refractory period). An atrial premature beat blocks down the fast pathway and conducts down the slow pathway, then re-enters retrogradely up the recovered fast pathway.

ECG: Regular tachycardia, rate 140–220 bpm. P waves are either buried within the QRS complex or visible immediately after the QRS as a pseudo-r' in lead V1 or pseudo-S in leads II, III, and aVF.

Acute Management Algorithm:

Vagal Manoeuvres: Modified Valsalva manoeuvre (straining to 40 mmHg for 15 seconds supine, followed by immediate passive leg elevation to 45° for 15 seconds) achieves cardioversion in >40% of cases (REVERT trial). Carotid sinus massage (auscultate for bruits first; massage 5–10 seconds unilaterally).

Intravenous Adenosine: First-line pharmacological intervention. Administered as a rapid bolus into a large antecubital vein followed by an immediate 20 mL saline flush. Initial dose 6 mg; if no conversion within 1–2 minutes, give 12 mg; if still unsuccessful, give a third dose of 18 mg. Adenosine activates A1 receptors on AV nodal myocytes, opening potassium channels and causing transient hyperpolarization and AV block (half-life <10 seconds).

Adenosine Precautions: Causes transient flushing, bronchospasm, and severe chest tightness. Contraindicated in severe asthma and decompensated COPD (use IV verapamil 5–10 mg instead). Dipyridamole blocks adenosine reuptake (potentiates effect; reduce dose). Theophylline and caffeine are competitive adenosine receptor antagonists (diminish effect; higher doses required).

Atrioventricular Re-entrant Tachycardia (AVRT) & Wolff-Parkinson-White (WPW)

WPW syndrome involves an anomalous extranodal muscular connection between atria and ventricles: the bundle of Kent . Resting baseline ECG demonstrates the classic triad: short PR interval (<120 ms), slurred initial QRS upstroke ( delta wave ), and prolonged QRS duration (>120 ms) with secondary repolarization abnormalities.

Orthodromic AVRT (95%): Antegrade conduction occurs through the AV node, and retrograde conduction travels via the accessory pathway. ECG shows a regular narrow complex tachycardia. Responds to vagal manoeuvres and IV adenosine.

Antidromic AVRT (5%): Antegrade conduction travels via the accessory pathway, and retrograde conduction proceeds via the AV node. ECG demonstrates a wide complex regular tachycardia mimicking ventricular tachycardia.

Pre-Excited Atrial Fibrillation (High-Yield Danger): Atrial fibrillation in a patient with WPW conducts impulses rapidly and directly down the non-decremental accessory pathway into the ventricles. ECG demonstrates an irregularly irregular, broad complex tachycardia with bizarre, polymorphous QRS morphology and varying delta waves at extremely rapid rates (often >250–300 bpm).

CRITICAL CONTRAINDICATION: AV nodal blocking agents ( adenosine, verapamil, diltiazem, beta-blockers, digoxin ) are strictly contraindicated. Blocking the AV node diverts all incoming fibrillatory wavefronts down the accessory pathway, accelerating ventricular response and directly triggering ventricular fibrillation and cardiac arrest .

Treatment: If hemodynamically compromised, immediate synchronized DC cardioversion. If stable, IV flecainide or IV procainamide (which prolong accessory pathway refractoriness). Definitive long-term cure is catheter radiofrequency ablation of the accessory pathway.

3. Broad Complex Tachycardias

A broad complex tachycardia is defined by a QRS duration >=120 ms. In clinical practice, any broad complex tachycardia must be assumed to be Ventricular Tachycardia (VT) until proven otherwise (~85% of all broad complex tachycardias, and >95% in patients with prior myocardial infarction or structural heart disease). The alternative differential is supraventricular tachycardia with aberrant intraventricular conduction (pre-existing or rate-related bundle branch block).

Electrocardiographic Differentiation (Brugada Criteria)

Features supporting ventricular tachycardia over SVT with aberrancy include:

AV Dissociation: Independent atrial and ventricular activity (P waves marching through at a slower, unrelated rate). Highly specific.

Capture Beats: A normal sinus impulse momentarily "captures" the ventricles via the normal conduction system, producing an isolated narrow QRS complex in the midst of broad-complex tachycardia.

Fusion Beats (Dressler Beats): Hybrid QRS morphology produced when a supraventricular sinus impulse and a ventricular ectopic impulse depolarise the myocardium simultaneously.

Extreme Axis Deviation: QRS axis directed into the "northwest quadrant" (-90° to 180°).

Concordance Across Precordial Leads: Uniformly positive or uniformly negative QRS complexes across leads V1 through V6.

Marked QRS Width: QRS duration >140 ms with RBBB pattern, or >160 ms with LBBB pattern.

Management of Ventricular Tachycardia

Pulseless / Unconscious: Follow Advanced Life Support (ALS) cardiac arrest algorithm: immediate CPR and unsynchronized high-energy defibrillation.

Sustained Monomorphic VT with Adverse Features (Unstable): Synchronized DC cardioversion under sedation.

Hemodynamically Stable Monomorphic VT: Intravenous Amiodarone (300 mg infused over 20–60 minutes via large vein, followed by 900 mg over the subsequent 24 hours). If pharmacological therapy fails, proceed to synchronized DC cardioversion.

Polymorphic VT & Torsades de Pointes: Polymorphic VT with a baseline prolonged QT interval (QTc >480 ms) is termed Torsades de Pointes ("twisting of the points"), appearing as QRS complexes that periodically twist around the isoelectric line.

Causes: Congenital long QT syndromes (LQT1/LQT2/LQT3, Romano-Ward, Jervell and Lange-Nielsen), electrolyte depletion (severe hypokalaemia, hypomagnesaemia, hypocalcaemia), and drug-induced QT prolongation (macrolides, quinolones, psychotropics, Class Ia/III antiarrhythmics).

Management: Discontinue all QT-prolonging medications. Administer IV magnesium sulphate (2 g bolus over 10 minutes) , even if serum magnesium levels are within normal limits. Correct hypokalaemia (target K+ 4.5–5.0 mmol/L). If recurrent, initiate overdrive transvenous pacing or isoprenaline infusion to accelerate basal heart rate and shorten ventricular repolarization.